
At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Results highlight the need for physicians to consider rheumatoid arthritis in patients with microscopic colitis presenting with arthralgia or other joint symptoms.

Chronic tophaceous gout was demonstrated to be an independent risk factor linked to the development of colorectal cancer.